Dr. Reddy’s Expands Access to Immunotherapy for Rare Head and Neck Cancer
JOHANNESBURG, South Africa / HYDERABAD, India, Aug. 3, 2026 Dr. Reddy’s Laboratories South Africa announced the registration of an...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
JOHANNESBURG, South Africa / HYDERABAD, India, Aug. 3, 2026 Dr. Reddy’s Laboratories South Africa announced the registration of an...
HYDERABAD, India, Aug. 1, 2026 Dr. Reddy’s Laboratories Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
BAD HOMBURG, Germany, July 31, 2026 Fresenius Kabi, an operating company of Fresenius, announced that both the U.S. Food...
ROTKREUZ, Switzerland, July 31, 2026 Polpharma Biologics International AG announced that the U.S. Food and Drug Administration (FDA) and...
